Structure Therapeutics (GPCR) vs Palvella Therapeutics (PVLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 75.5% versus a loss of 9.8%. Palvella Therapeutics is the larger company by market cap ($1.89 billion vs $1.83 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | PVLA |
|---|---|---|
| Share price | $25.67 | $131.34 |
| Market cap | $1.83B | $1.89B |
| 1-day change | -3.79% | +0.57% |
| YTD return | -63.09% | +25.48% |
| 1-year return | -9.77% | +75.47% |
| 5-year return | — | -63.60% |
| EPS (TTM) | $-3.03 | $-4.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-141.20M | $-41.72M |
| 52-week high | $94.90 | $161.38 |
| 52-week low | $25.09 | $65.93 |
| Distance from 52-week high | -72.95% | -18.61% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +312.08% | +75.52% |
| Average volume | 965.00K | 211.36K |
| Shares outstanding | 71.31M | 14.41M |
| Employees | 281 | 29 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed GPCR by 85.2 percentage points over the past year.
- The two companies sit in different sectors: Structure Therapeutics in Healthcare and Palvella Therapeutics in Health Care.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Healthcare · Biotechnology · 281 employees
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
GPCR vs PVLA FAQ
Which is bigger, Structure Therapeutics or Palvella Therapeutics?
Palvella Therapeutics (PVLA) is larger, with a market capitalization of $1.89B compared with $1.83B for Structure Therapeutics (GPCR).
Which stock has performed better over the past year, GPCR or PVLA?
PVLA returned +75.47% over the past 12 months, compared with -9.77% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Palvella Therapeutics in the same industry?
No. Structure Therapeutics is in the Healthcare sector, while Palvella Therapeutics is in Health Care.